Best Series A Biotech & Life Sciences Investors 2026

Biology is programmable. We invest in visionary entrepreneurs whose platform-level science innovations rewrite operating systems across biology, materials, diagnostics, and AI. By backing founders developing programmable biology, synthetic biology, advanced materials, computational therapeutics, and biotech infrastructure, we enable the creation of breakthrough technologies that solve global challenges.

The best biotech companies come from deeply technical founders with direct research expertise. We back early-career scientists, often PhD holders who have never written a business plan, providing capital, mentorship, and partnership to help them build world-changing technologies.

Transform academic discoveries into breakthrough therapeutic companies. Partner with exceptional founders to build sustainable biotech companies with significant commercial opportunity. Leverage in-house discovery engines to de-risk company creation and accelerate time to clinic.

Back exceptional inventors building their own enduring businesses in life sciences. Founders who design the initial conditions of a company have superior odds of creating transformative value.

Healthcare's largest markets are ripe for disruption through software-first solutions. We back companies advancing care delivery through new technologies and care models, and software-first techbio platforms that transform drug discovery and therapeutic development.

We invest in people solving difficult problems and building category-defining products in healthcare. We partner with visionary leaders at the intersection of medical technology and digital health to create transformative solutions that improve patient outcomes.

Invest in early-stage digital health companies that empower informed, connected health consumers to make confident decisions about their health. Focus on removing friction from healthcare, providing transparency, and enabling people to take control of their health journey through technology. Particular emphasis on solving structural problems in chronic disease management, mental health, reproductive health, aging in place, and specialty care navigation.

Inflect Health invests in visionary entrepreneurs building category-defining solutions to transform healthcare. Unlike traditional VCs, Inflect's success metric balances financial returns with health outcomes improvement. We back founders with clear vision, diverse teams, and passion for healthcare transformation. Our physician-led partnership brings 45+ years of healthcare operational expertise and direct access to 8,000+ clinicians, enabling hands-on partnership from design through go-to-market.

Solving the world's biggest challenges by supporting the world's best entrepreneurs in food and agriculture. Focus on sustainable, scalable solutions to global food security through innovation in alternative proteins, ingredients, and food technology.

Deep health emerges at the convergence of advances in biology, chemistry, AI/ML, robotics, and clinical medicine. We back visionary founders addressing root causes of chronic disease across three domains: biology within us (biotech platforms), environment around us (environmental/chemical health), and systems that care for us (healthcare delivery innovation).

Fund and build next-generation life sciences companies solving important healthcare needs through cutting-edge breakthroughs in medicine and science. Partner closely with management teams to maximize returns across all portfolio companies through hands-on operational support, strategic guidance, and access to networks of experienced life science leaders.

Healthcare is one of the most compelling long-term investment opportunities globally, driven by aging demographics, rising healthcare spending, and continuous scientific innovation. We invest across the entire healthcare value chain to drive innovation and address unmet medical needs.

Early-stage companies leveraging frontier technologies (AI, gene editing, synthetic biology, advanced diagnostics) to transform human health, cure disease, and strengthen global resilience. Data-driven, engineering-first approaches combined with cellular biology create transformative healthcare companies. Focus on companies that solve problems affecting everyday people globally with platform potential across multiple indications and therapeutic pathways.

Translating groundbreaking science into life-changing medicines through seed-led investment model emphasizing science-first, patient-centric, collaborative approach. Play the long game with urgency - combining patient discipline with speed to market.

Create first-in-category bioplatform companies through scientific innovation and systematic entrepreneurship. Combine institutional scale with pioneer creativity to build breakthrough life sciences companies.

Healthcare innovation is a team sport. We identify promising healthcare technologies early in their life cycle and invest much more than capital to help our teams become world-class enterprises. We provide clinical expertise, operational guidance, and network access from a team of practicing physicians and healthcare operators.

Explicitly structured to eliminate animals from food supply chain. Invests in innovative early-stage companies across food, beverage, and biotech driving healthier, humane, sustainable future. Optimizes for impact on animal numbers alongside commercial success.

Breakthrough science merged with operational rigor creates transformational opportunities in life sciences. We identify emerging fields at the intersection of science and unmet medical need, then actively shape company formation working with scientific founders and expert advisors to design strategy from inception.

Life sciences is experiencing unprecedented innovation through TechBio—companies that merge technology and biology. We partner with passionate, accomplished founders with unique insights to solve daring life science problems and significantly impact patient care. We provide capital, operational support, scientific guidance, and industry relationships to build transformative companies.

Science-backed sleep solutions will dominate the market. We invest in innovative solutions across all sectors aimed at improving sleep, applying advanced sleep science to support portfolio companies.

Back global-minded founders with cross-cultural perspectives and lived experience solving structural healthcare inequities. We invest at the intersection of clinical expertise and technical execution, deploying human capital, financial capital, and cultural capital to support founders building solutions that improve patient outcomes, lower costs, enhance patient and provider experience.

Systematically back clinically rigorous, behaviorally grounded wellbeing startups tackling stigmatized areas—alcohol use disorder, menopause, mental health—using stigma as an investing edge and insisting on consumer-grade UX. Solve the Wellness Gap: the quantifiable delta that has grown as GDP per capita increased while physical and mental health stagnated.

Invest in visionary technical founders building frontier healthcare solutions at the intersection of novel science and deep technology. Focus on 'hard problems' requiring scientific innovation and engineering excellence—neurotech, AI-driven biology, AR/VR medical applications, and novel care delivery models. Partner with founders (especially scientists and engineers from academia transitioning to entrepreneurship) who are fundamentally changing how healthcare works.

Venture capital can do more than fund companies—it can create them from the ground up. Newpath Partners specializes in building biotechnology companies in partnership with leading academic scientists, focusing on breakthrough biology platforms in gene editing, regenerative medicine, and transformational therapeutics that address the greatest unmet medical needs.

Balderton Capital backs European-founded technology companies with visionary founders building transformative businesses. The firm combines patient capital, operational expertise, and founder support to enable European entrepreneurs to build world-class companies.

Backing founders transforming biology into an engineering discipline. We invest in the infrastructure stack of biology—synthetic DNA, cloud labs, automated experiments, computational drug design, and AI-for-biology—enabling science as a software problem at scale. We partner with technical founders who apply engineering rigor to biological challenges.

Co-found and build breakthrough life sciences and deep-science companies with university researchers. Follow science to create revolutionary technologies that prevent, detect, and cure disease. Patient capital from concept stage through commercialization.

Breakthroughs at the convergence of technology, science, and humanity improve how we live, work, and experience the world. We invest in transformative technologies for human performance and wellbeing.

The best healthcare solutions emerge from teams that deeply understand real-world clinical challenges. We embed 650+ clinicians as partners in deal sourcing, diligence, and portfolio support. Unlike traditional VCs, we connect founders with authentic practitioners who understand unglamorous but deeply human healthcare problems.

Contrarian venture firm investing in scientific and technical breakthroughs. We identify white-space opportunities where technical founders are solving previously unsolvable problems. We combine capital with deep domain expertise, research capabilities, and operational support to help founders scale from idea to commercialization.

Driving positive, lasting change in food and agriculture creates exceptional financial outcomes. Impact and return aren't trade-offs—they're intertwined. Both are essential. We invest in technologies and companies addressing human health, planetary well-being, responsible production, and climate solutions.

Science-driven venture capital focused on breakthrough healthcare innovations. Deep scientific rigor in diligence with mechanism-of-action understanding, proof-of-concept validation, and extensive KOL/clinician engagement. Backed by Zambon Group pharmaceutical expertise.

Data equals human potential. Humans and machines converging will unlock profound innovations across every industry. We support founders solving technical and impactful problems to build a tomorrow where humans thrive through AI and frontier technology.

Atinum Investment identifies and invests in companies solving fundamental problems through technology innovation and market disruption. The firm specializes in growth-stage startups and paradigm-shifting companies across diverse sectors.

Longevity is a completely new industry within biotech requiring founders who can think differently. Mission-oriented, founder-led companies with unconventional backgrounds will prove most effective at bringing the first longevity drugs to market and extending human healthy lifespan. The field is at a critical inflection point where we will either breakthrough to mainstream or get silo'd in a funding winter.

Civilization Ventures backs exceptional scientific founders—particularly PhDs and postdocs from elite institutions—building essential innovations in health tech and biology. We believe the best breakthroughs come from disruptive science combined with founder determination. We provide 'mentor capital': not just capital, but active operational guidance, scientific rigor, and access to our network of Fellows, Advisors, and portfolio founders.

Partner with mission-oriented founders working on transformational ideas that use science and technology to improve human health and better humanity in lasting ways. We seek founders who bring deep technical expertise and commitment to solving complex scientific and healthcare challenges.

Funding the next generation of contrarian founders building breakthrough longevity biotech companies. We invest in the transition from sickcare to healthcare by extending healthy lifespan and preventing age-related disease.

Building next-generation food and agriculture technology companies that commercialize solutions for sustainable production, equitable distribution, and healthy consumption. Partners with strategic investors to drive systemic impact in food systems.

Technology and biology are converging to create the next generation of transformative companies. The digitization of life sciences—driven by exponential growth in biological data and advances in AI/ML—is enabling a new class of platform companies that will dominate the industry. Tomorrow's biotech will be built by teams of three: a biologist, a chemist, and a computer scientist.

Apply revolutionary biotechnology to replace industrial inputs with biology-based alternatives, transforming how the world manufactures chemicals, materials, foods, and medicines. Synthetic biology is a $25T opportunity spanning industrial inputs, food & agriculture, pharmaceuticals, and specialized applications.

Backing transformative founders building exceptional companies across all sectors

Complex health problems require multidisciplinary teams combining deep technical, financial, and domain expertise. We invest in breakthrough science and technology-enabled solutions across human and animal health.

Back transformational healthcare companies at pre-seed through Series A that leverage technology to improve patient outcomes, healthcare operations, or clinical delivery. Partner with founders who understand both healthcare workflows and technology innovation deeply.

Make no little plans. Support revolutionary (not evolutionary) ideas that transform industries and benefit society. We partner with entrepreneurs solving massively multi-disciplinary problems at the intersection of AI, data, biotech, and deep tech. Our style of in-the-trenches venture capital doesn't scale—we make fewer than 10 investments per year so we have time to roll up our sleeves with every team we back.

We invest in transformative frontier science and technology that most VCs avoid. Our focus is on biotech, deep tech, psychedelics, brain-computer interfaces, life extension, and infrastructure bets in undercapitalized global markets. We believe the biggest winners in biotech are companies producing quality-adjusted life years (QALYs).

AI and ML techniques represent a transformational competitive edge with clear value delivery. Technical founders building intelligent B2B products will drive the next wave of billion-dollar companies across biotech, infrastructure, security, and enterprise software.

Climate restoration through identification and scaling of 'n of 1' technology opportunities combining innovative tech, viable business models, and visionary leadership. Focus on achieving $1B+ valuations in <10 years with 'scale and speed' mentality.

Spark Capital backs transformative products built by creators with genuine vision and technical depth. We believe that the best way to evaluate a founding team is not through credentials or market analysis, but by experiencing their product firsthand. Product comes first, and everything else follows.

We back the foundational layers of progress. Developer platforms that accelerate creation. Robot operating systems that make autonomy real. Simulation engines training the next generation of AI. Formal verification securing billions in value. Foundational systems that quietly compound—built by founders who see elegance in complexity and possibility in constraints.

Cannabis is fundamentally a technology and compliance problem. We back companies building essential infrastructure—software, hardware, data, and supply chain systems—that enable the regulated cannabis industry to operate efficiently and scale.

We refuse to compromise between doing good and delivering strong financial and commercial returns. Portfolio companies gain access to TELUS's commercial networks, data-rich platforms, and deep expertise across agriculture, health, and connectivity giving them a unique edge as they scale.

Fund companies that help people live longer and live better through science and technology. We support exceptional technical founders solving real health and happiness problems with scientific rigor and consumer appeal. Our data-driven methodology and proprietary ML platform identify outsize return potential in complex early-stage companies.

Support early-stage founders solving real problems through technology with conviction-driven, low-volume approach. Emphasize companies addressing fundamental shifts in software economics as LLMs drive creation costs to zero. Partner deeply with founders combining institutional investing expertise with hands-on operational mentorship.

The most enduring companies are created by founders willing to commercialize real science and scale real systems. We focus on hard tech at the intersection of computation and physical sciences—aerospace, biotech, energy, materials—where technical execution is the moat.

Data, cloud, and hardware advances will create unprecedented opportunities for great companies to be built. We invest in founders with big ideas and deep tech who are building infrastructure and value chains around data. Great people are the key to company success. We provide operational expertise, strategic guidance, and access to networks of mentors and international partners, particularly in China and Asia-Pacific.

The best companies will be built by technical founders - engineers, researchers, and scientists who have experienced a problem viscerally and are compelled to solve it. We invest in tools, platforms, and infrastructure for technical builders, and we partner with founders to help them evolve into leaders of generational companies.

Canadians have built over $1 trillion in enterprise value globally, yet were initially backed by US VC not Canadian investors. We back founders with Canadian roots—regardless of where they build—because exceptional talent from Canada represents a sustainable, quantifiable selection edge.

Back dual-use technologies serving both commercial and government markets. Founded as investment community response to 9/11, we bring unmatched expertise from NSA, CIA, DARPA. We seek founders building innovative cyber, AI safety, and advanced technologies with meaningful impact on national security and commercial markets.

The era of transformational science is here. Life sciences and industrial markets are being reshaped by founders who move fast and build at the intersection of biology, chemistry, computation, and AI. This is a step-change in how science becomes solutions. We back bold founders who go beyond solving technical problems to redefine entire markets.

Back founder-operators with prior venture-scale exits solving hard technical problems in non-obvious, regulated deep-technical verticals including AI infrastructure, blockchain, biotech, and communications infrastructure. Co-invest alongside quality partners to maintain flexibility and focus on deep operational support and strategic value-add.

Support visionary founders building transformative technologies across blockchain, AI, and biotechnology. Provide capital, technical resources, and access to Binance's 300M+ user base and infrastructure. Partner for long-term value creation with founder-centric approach.

We invest in early-stage information technology and biotechnology companies in Colorado and the Mid-Atlantic. Our philosophy is rooted in mountain guide principles: careful pattern recognition under uncertainty, patience in waiting for proper conditions, and a commitment to realized returns over paper valuations. We provide hands-on operational partnership, board-level involvement, and access to deep regional networks built over decades.

The primary constraint for seed-stage, science-based entrepreneurs is access to experienced business judgment. CDL provides objective-based mentoring from accomplished entrepreneurs, angels, and scientists to help founders prioritize tasks and de-risk their businesses.

Early-stage venture capital for IT and Biotech companies in Colorado Front Range and Mid-Atlantic. Focus on experienced founding teams solving important problems with potential for significant financial returns. Patient capital approach with operational support and deep regional networks.

We believe the greatest advancements of our lifetime will be the result of reprogramming chemistry and biology using creative technology platforms. We invest at the frontier of science, supporting founders re-architecting the world at a molecular level.

Social impact companies are undervalued at the earliest stages when metrics are unclear. We invest very early in mission-driven founders tackling the world's hardest problems, supporting them until they're attractive to top-tier VCs. 12-15 exceptional entrepreneurs can solve the largest global challenges.

Biology is the next frontier of technology. BABEL believes early-stage consumer biotech can solve macro problems (food security, climate, health) while delivering outsized returns. The best outcomes come from diverse, science-credentialed founder teams with deep domain expertise and commitment to sustainability and impact.

Back mission-driven founders addressing significant global challenges through leading-edge technology. Provide flexible and patient capital, leveraging our time, resources, and networks to support portfolio company success. Focus on founders with authentic social and environmental missions alongside commercial viability.

Material science and deep tech innovations drive outsized returns while solving urgent human problems. We back inception-stage founders turning lab breakthroughs into commercial products that make the world cleaner, more productive, and healthier.

Invest in only two kinds of technologies: those that move humanity toward utopia, and those that hold the line against oblivion. Back n-of-1 visions for an era of Black Swans—unconventional companies solving civilization-scale problems that others dismiss as too early, too risky, or too misunderstood.

Expertise unlocks AI's full potential. We back technical founders who harness deep domain knowledge, apply novel AI applications, and push boundaries to create transformative breakthroughs in healthcare, life sciences, and enterprise.

Investing in breakthrough deep technologies that address humanity's greatest challenges. We allocate ~80% to climate solutions (carbon-negative materials, renewable energy, climate adaptation) and ~20% to frontier tech (aerospace, robotics, advanced materials, biotech). We operate as a venture-and-philanthropy platform backed by the Fukutake family, blending profit-seeking with impact objectives.

Progress in food, agriculture, and human health lags other sectors due to structural constraints. We invest in deep technologies that remove these bottlenecks at scale—whether AI, biology, robotics, or materials science. We're not intimidated by threats to the status quo.

The biggest companies of the century will be built solving the world's most pressing problems. We champion ambitious founders using technology to reshape civilization around climate, health, and inclusive capitalism.

Gender-diverse teams produce superior returns on equity. We fund exceptional women-led startups where women hold meaningful operating C-suite roles and own substantial equity. Research shows companies with diverse female leadership are 39% more likely to be above-average profitable, 30% more likely to outperform, and 20% more likely to improve business outcomes.

Expand the AI ecosystem by backing technology visionaries solving complex problems to reshape our world. Focus on game changers and market makers in AI, robotics, biotech, autonomous vehicles, and applied AI. Leverage NVIDIA's unique position as GPU infrastructure leader to identify and support companies that will drive adoption of NVIDIA technology.

Southern California's original seed-stage venture capital fund, focused on capital-efficient technology startups with differentiated competitive advantages targeting large, addressable and growing markets outside the Bay Area. Active, hands-on management with emphasis on venture fundamentals and disciplined investment strategy.

Where breakthrough science turns into world-changing companies. We back scientists and engineers at the earliest stages—pre-formation and pre-product—at the intersection of AI, engineered biology, next-gen compute, and hard science. If it's too early for everyone else, it's probably right for us.

Early-stage innovation from founders backed by seasoned operators. We invest in disruptive technologies solving real problems at the intersection of scientific breakthroughs and practical execution. Our founders get patient capital, hands-on mentorship from 100+ years of combined experience, and access to our network for strategic growth.

Early-stage deep tech entrepreneurs developing novel, patented solutions to the world's biggest problems in robotics, quantum computing, energy, climate, and healthcare. We back visionary founders with deep domain expertise and engage as thought partners through technology validation and commercialization.

Apply AI and data science to identify and invest in N-of-1 companies with 10-100x potential. Back founders who expand individual freedom and decentralize power. Invest in companies that embody principles from the Bill of Rights (voice, fair process, proportionality, user power) and Bitcoin whitepaper (trust-minimized, verifiable, aligned incentives, open access).

We invest exclusively in AI-first companies where advances in artificial intelligence are the primary driver of product capability, competitive advantage, and long-term value creation. We are deeply coupled to the frontier of AI research and industry, enabling us to identify emerging technical inflection points and structural shifts early.

Support passionate founders forging the future. Invest in seed and early-stage companies with unique ideas that have potential to reinvent entire industries. Focus on frontier technologies that make the world better and don't prey on human frailty.

We back determined builders working on hard problems in critical domains. Real innovation is non-obvious at first and often misunderstood. We support contrarian founders during frontier exploration when they need it most.

Investing at the intersection of for-profit and for-good. Companies that make the world better AND deliver strong financial returns. The Villain Test ensures both impact and profit alignment.

Partner with visionary founders to turn bold ambitions into world-changing breakthroughs in life sciences, technology, healthtech, and crypto. Distinctive 'technical-risk-yes, regulatory-risk-no' filter ensures clear pathways to success.

We back bold, ambitious, and resilient founders driving breakthrough innovations in HealthTech, CleanTech, and AgriFoodTech. Female-led and gender-mixed teams deliver superior returns and drive meaningful impact. Over five decades of combined experience navigating financial cycles enables us to partner authentically with founders, providing not just capital but strategic guidance and operational support.

Founders building the possibly impossible deserve capital plus marketing support. Great technology combined with exceptional storytelling and narrative development creates world-changing moonshots. We provide both the capital and the story-telling expertise to help founders achieve escape velocity.

Invest in early-stage companies using disruptive deep tech to upend unit economics of established industries while delivering climate-positive outcomes. Focus on undercapitalized climate verticals (water, agriculture, robotics, materials, energy) where deep tech can achieve 2.5-3x unit economics improvement paired with environmental benefits.

Early-stage Latin American entrepreneurs solving critical healthcare, environmental, and societal challenges using science and technology. We provide capital, Silicon Valley networks, and operational expertise to build transformational companies.

Climate is the biggest challenge of our lifetime and the greatest business opportunity of the coming decades. We back visionaries accelerating climate innovation that will reshape our global economy for the betterment of people and planet. The most successful companies are born from a vision for a better future and the ability of that vision to create large, lasting positive impact. We invest in frontier technologies addressing climate across seven sectors: Built Environment, Carbon Management, Compute, Energy, Food & Agriculture, Manufacturing & Industrials, and Mobility. The best ideas come from everywhere—we operate where many venture firms can't or won't.

Impact and profit are inseparable. We back visionary founders solving humanity's toughest problems in healthcare, AI, robotics, defense, and automation. We measure success in lives saved as well as returns.

AI Eats Software. Over the next decade, virtually every bit of software will be replaced by artificial intelligence. We invest in founders and entrepreneurs who understand the transformational power of AI and are building solutions that reshape how we live, work, and play.

We back MIT founders building deep-tech companies with defensible science or engineering advantages. We support the transition from researcher to founder, providing both capital ($500K-$5M) and operational support through the MIT ecosystem.

Intelligence is coming into the physical world through AI and robotics applied to atoms rather than bits. We back capex-heavy, long-horizon bets in hard-to-abate decarbonization sectors and hardware-heavy industrial systems that many traditional early-stage funds avoid.

Technology can have a highly disruptive impact on society. We back founders on the forefront of innovation with clear vision towards positive change, leveraging domain expertise to ensure value creation. Founder-first approach with operational support.

We invest in category-defining companies at Pre-Seed and Seed stages founded by entrepreneurs with authentic passion. Focus on founders working in climate, food, healthcare, AI automation, and frontier technologies. Philosophy: when the world says No, go toward the Yes as hard as you can.

Partner with spiky founders building category-defining companies using novel technological approaches. Focus on AI-driven innovation across alternative architectures, custom software, research assistants, TechBio, infrastructure, and enterprise applications. Provide capital, operational support, strategic guidance, and network access for founders with unique insights and deep technical expertise.

We back 'sub-0.1% of the population' type exceptional founders building fundamental, infrastructure-level technologies in critical sectors (computing, defence, energy) reshaping our world. Community-driven approach provides proprietary deal flow and deep technical credibility. Focus on first cheques in pre-seed/seed with hands-on mentorship and network access.

We invest in technically sophisticated founding teams solving breakthrough problems in deep-tech. We believe the next generation of transformational companies will be built by scientists and engineers with deep domain expertise tackling problems at the frontier of AI, cybersecurity, quantum, robotics, space, synthetic biology, and bioengineering. We provide patient capital and technical partnership to help these teams achieve escape velocity.

The $12 trillion food and agriculture industries still rely on centuries-old methods. We back disruptive science and technology to modernize the food system—from biotech and sensors to automation and software—to feed 10 billion people by 2050 while preserving nature and nurturing humankind.

Back the global winners of tomorrow through disciplined venture capital and growth equity investing. We are a trustworthy partner providing capital, operational expertise, and access to pan-Asian networks. Fund-oriented professional VC with fundamental philosophy of quality, responsibility, and stability.

The most valuable companies of our time will be the ones solving humanity's biggest problems across planetary health, human health, and economic health. We back exceptional founders building breakthrough solutions that create both financial returns and positive impact.

Deep tech startups at the edge of what is possible solve critical human and planetary health problems. SOSV backs founders combining scientific rigor with entrepreneurial grit, providing not just capital but access to specialized labs, manufacturing, and global expertise networks.

Back extraordinary entrepreneurs throughout the company-building lifecycle from seed to IPO. Combine venture capital expertise with BCG management consulting to accelerate value creation. Support founders with capital, strategic guidance, and access to global networks.

We back founders on a mission to industrialize scientific and technological progress. Hardtech startups solve difficult technological problems using interdisciplinary mixes of technology and engineering. We provide patient, supportive capital and community to help founders navigate R&D cycles and build technically defensible products.

The AI-first transformation of business will be as big as digital, mobile, and cloud combined. We invest in companies building the AI-first technology stack: data foundations, AI tools, autonomous applications, and product-led growth companies that accelerate adoption. Founders building at any layer of this stack can reach goals and uncover opportunities previously unattainable.

Technology will define geopolitics. We invest in the Freedom Stack—foundational technologies critical to American national security and technological leadership. We partner with mission-driven founders building capabilities essential to American prosperity and strategic advantage.

Permanent balance-sheet investor backing highly defensible, category-defining, mission-driven companies solving the world's biggest problems. Focus on founders transforming legacy industries with emphasis on diversity, equity, and inclusion.

Invest in century-defining technologies and companies. Focus on infrastructure-oriented, cross-vertical applied AI for physical-world and life-science problems, with deep healthcare systems expertise. Transform industries through foundational technology breakthroughs.

Women founders represent an overlooked asset class that delivers superior returns. Women-founded companies earn 26% more for investors, yet receive only 2% of venture funding. We invest exclusively in women-founded companies, providing capital, network access, and operational support to drive transformative change.

Women-led fund focused on healthcare infrastructure—middleware, payments, clinical trials, and data architecture—thesis-driven, GTM-heavy partner offering hands-on commercialization support for technical founders scaling into payer and provider markets.

Invest in companies addressing fundamental societal needs. Provide Talent/Capital/Attention platform via in-house content and advisory network. Mission-driven investments with specialized expertise in healthcare, climate, robotics, and deep tech.

Partner with elite founders building transformational technologies that create lasting economic and societal value. Focus on Smart Enterprise across five sectors: Logistics, Life Sciences, Healthcare, IT Infrastructure, and Government/Defense. Invest in platforms that enable human experts to solve non-linear problems through data integration and network effects.

Acequia Capital partners with technical founders and product teams building the next wave of global businesses. They provide more than capital—experienced operators offer strategic guidance on product roadmap, technology strategy, business model, and GTM execution. The firm is a center of a global innovation ecosystem with unique capability to detect earliest signal in emerging technology trends.

Humanizing deep tech by bringing advanced breakthrough technologies to where the people are and maximizing the value they generate for solving humanity's most critical crises. We invest in companies addressing climate, manufacturing labor shortages, healthcare costs, sustainable food production, and computing infrastructure.

Mayfield invests in founders building iconic companies through AI-first innovation and human-AI collaboration. The firm believes the next wave of category-defining enterprises will leverage collaborative intelligence, where AI teammates augment and amplify human capability. Mayfield seeks deep tech founders with defensible innovation, clear market advantage, and the ability to scale globally.

Frontier technologies and medical breakthroughs offer the best opportunities to address fundamental human and environmental challenges. Diversity of founder backgrounds drives innovation and superior returns. Founders with domain expertise, technical credentials, and distinctive visions solve the world's biggest problems.

First women-led VC investing in underrepresented founders solving underserved problems in undercapitalized geographies. We capitalize on three biggest arbitrage opportunities: diversity of founders, geographic expansion beyond Silicon Valley, and problems with meaningful social impact. We back exceptional teams in consumer tech, digital health, and future of work sectors.

We back dropouts, renegade students, and deep-tech scientists working on ideas that would appear in science fiction. We exist to prove that great founders don't need university degrees and are found in the oddest places. We invest at inception stage (R&D through Seed), providing capital, mentorship, community access, and operational support. People-first approach: it's more about the who than the what.

Support founders pursuing their life's work with an alternative to the hype cycle: the luxury of long-term thinking. We support founders building category-defining companies across all sectors that will last for lifetimes.

Deep technology and hard tech company investing at inflection points. Partner with technical founders building infrastructure-level solutions for global scale. Founded 2010 on belief that next generation of transformative companies require deep technical expertise, not just capital.

Back passionate, emerging talent solving deep technology challenges. Support founders from napkin-stage through IPO with patient, flexible evergreen capital. Focus on biotechnology, frontier software, food innovation, longevity, and AI that maximize impact and potential.

Story invests in the building blocks of automated systems across three interconnected layers: sensory systems (data capture), data processing (organization and structure), and machine intelligence (applications and decision-making). We believe the most impactful problems require the most innovative solutions, and we partner with founders pursuing audacious, challenging businesses because that's what it takes to create lasting impact.

We partner with visionaries building enduring moats in deeptech and gaming. We invest up to $12M from inception to Seed. We restore the original essence of venture capital - working directly with bold entrepreneurs to tackle the world's toughest challenges through breakthrough physical technologies and novel gaming experiences.

Great entrepreneurship exists everywhere—not just in traditional tech hubs. We invest in high-potential early-stage founders with a focus on underrepresented geographies (Midwest, Latin America) and demographics (women, minorities, immigrants). Beyond capital, we provide strategic guidance, ecosystem connections, and relocation support through our Tulsa-based infrastructure.

Invest in talented people solving challenging problems. We back extraordinary founders building products that people want with speed, efficiency, and operational excellence.

Generalist investors with vertical expertise. We invest in bold, broad, multi-vertical technology companies applicable to multi-trillion dollar industries (real estate, finance, insurance, sustainability). Our distinctive Moderne Passport program creates value by connecting 1,500+ corporate executives with portfolio companies, generating customers, strategic partnerships, and operational guidance.

NEA partners with ambitious founders at every stage of company building, from pre-seed through IPO. They invest at the intersection of technology and healthcare, believing the most transformational innovation occurs where deep domain expertise meets world-class technical founders. NEA serves as both capital provider and active operator.

We democratize venture capital by providing individual accredited investors with professional-grade access to elite venture opportunities. We leverage our massive 850,000+ community network and 11,000+ investors to create unique value for founders, sourcing and diligencing deals alongside top-tier VCs (a16z, Sequoia, Khosla) without leading rounds. Our network is our competitive advantage—it compounds value for all stakeholders.

As the world becomes more information-rich, most transformative new companies will leverage data science, machine learning, and advanced computing power. We back founders building breakthrough solutions at this intersection.

Invest in deep science and disruptive technology companies that solve fundamental human problems—inequality, health, climate adaptation. We back founders with vision, instinct, and drive to scale impact.

Rewriting the VC rulebook to deliver high returns with high impact. We invest in founders building climate and social impact technologies with intentional, measurable, net-positive outcomes at meaningful scale.

Identify exceptional founders and unique talent combinations building contrarian, under-the-radar technology solutions. Provide hands-on support, operational guidance, and board-level involvement to early-stage Series A and B companies, primarily in Southern California. We fight for our founders and expect all investments to succeed.

Boom Capital invests early in founders building at the frontiers of science. We position founders as scientist-protagonists and back highly technical teams tackling ambitious, non-obvious problems in genomics, machine intelligence, aerospace, new chemistries, and related deep science sectors.

The most defensible companies are built on hard technology solving real problems at scale. We partner with technical founders leveraging deep domain expertise and the Tsinghua network to identify and nurture transformative innovations in deeptech, healthtech, and the data economy.

Back founders building iconic companies that transcend boundaries. We invest directly in their growth to make them unbreakable. Founded on principle that luck isn't made, it's engineered. Founders are our customer, not LPs. We always vote shares with founders and provide 1% non-dilutive founder development capital alongside every first check.

Women receive only 2% of venture capital despite female-founded startups delivering 2x return per dollar vs. all-male teams. The Helm invests in game-changing, undervalued companies at seed stage founded by women, providing not just capital but operational support and ecosystem access.

Exceptional founders living in the future deserve operators who provide more than capital. We partner with founders on go-to-market, brand, storytelling, and team building.

We build category-defining companies through a combination of design, product, operations, and capital. We identify market gaps, pair brilliant founders with Expa's studio resources, and help them build companies that reshape entire industries.

K5 Global backs category-defining companies from inception to IPO. The firm leverages exceptional networks across media, entertainment, politics, finance, and technology to provide strategic value beyond capital. We believe the best companies are built by founders who can access world-class talent, capital, and strategic relationships.

Technology-based economic disruption of large markets through black swan investments. We seek founders with domain expertise and unreasonable conviction to build billion-dollar companies solving the world's largest problems.

Prime Movers Lab partners with serial entrepreneurs building breakthrough scientific companies that tackle the world's biggest problems. We believe the best venture partners provide operational excellence, technical expertise, and hands-on support—not just capital. We invest in companies reinventing energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.

Invest in advanced technologies solving the world's greatest challenges in energy, environment, food safety, sustainable manufacturing, healthcare, and education. Back contrarian founders building capital-intensive, deep-tech ventures that address survival-driven global needs. Bridge breakthrough technologies from developed markets into emerging economies and vice versa. Create high-return, high-impact outcomes through hard technology.

We back bold founders and AI-enabled, game-changing innovations that improve planetary and population health. We target capital-efficient, highly scalable startups reimagining sectors like agri-food, climate, fintech, life sciences and nutrition through deep tech and proprietary IP. We engineer outcomes through operational support, strategic partnerships, and sector expertise.

We back technically ambitious founders building tomorrow's most iconic companies in frontier sectors like AI, hardtech, robotics, healthcare, and fintech. We believe great companies come from founders willing to tackle complex problems that generalist funds avoid.

Battery Ventures operates as a stage-agnostic firm backing technology-driven category leaders across all growth stages from seed to buyout. The firm believes the best tech investments span the entire founder journey, and they practice collaborative, research-focused investing with embedded operational support through their Portfolio Services platform. They seek technical founders with deep domain expertise and experienced operators building in four core sectors: Application Software, Infrastructure Software, Consumer, and Industrial Tech + Life Science Tools.

Back technical teams working on breakthrough products. We invest in seed stage companies that demonstrate technical differentiation - meaning technical or product-level superiority is a major reason for future success. We pursue investments from application layer (AI/ML) through software infrastructure to hardware layers (semiconductors, photonics).

Transformative national security solutions emerge from early-stage private-sector startups developing frontier technologies. IQT identifies, evaluates, and leverages innovations to accelerate government adoption while enhancing commercial success.

We invest in the Super Evolution—the convergence of ubiquitous sensors, advanced machine learning, cloud systems, robotics, 3D printing, and CRISPR. We partner with technical founders solving hard engineering and science problems to rethink large industries and tackle humanity's most pressing challenges.

Back exceptional founders early, globally. Self-funded model enables founder-first alignment, rapid deployment, and direct support. We believe the best companies come from the best founders, regardless of background or current stage.

North Africa and Africa possess tremendous entrepreneurial talent. Strategic capital combined with operational expertise can unlock transformative solutions that reshape industries. We invest in founders solving region-critical problems.

We back entrepreneurs using computational approaches (AI, simulation) to solve trillion-dollar problems in climate, health, industrial transformation, and national security. Deep tech requires patient capital and scientific rigor.

We back outliers of the outliers - founders with unreasonable ambition who can filter out 95% of conventional VC advice. We seek category-defining companies aiming for $10B+ outcomes, not incremental improvements. Our conviction is deep, selective, and global. We don't meddle - we provide brutal honesty, talent upgrades, and capital for survival through near-death moments.

We invest in the most promising entrepreneurs building the fastest-growing early-stage startups. We provide cross-border access by connecting founders to resources and networks across the world's most valuable and influential VC markets.

Celesta invests in brilliance at the forefront of science and engineering, targeting companies that enable mass adoption of emerging tech, radically improve health outcomes, and transform large industries. Focus on platforms enabling emerging tech adoption, bioconvergence innovations (high-tech + biotech), and technologies disrupting legacy industries with deep tech.

We are professional fixers for complex situations. An extension of your team. Fierce defenders when you need us most. Partners who roll up their sleeves. We invest in early-stage companies helping them avoid traditional roadblocks on their path to hypergrowth. We specialize in navigating hostile situations, IP protection, and crisis management.

Mubadala partners with world-class companies and institutions to drive transformational growth across strategic sectors and geographies. We believe in long-term value creation through patient capital, operational expertise, and global partnerships aligned with Abu Dhabi's economic diversification.

We combine world-class AI analytics with industry-leading networks to identify exceptional companies and make rapid investment decisions. Great companies, regardless of sector or geography.

Turn sci-fi into sci-fact by backing founders solving the most vexing puzzles facing humanity. We believe in counter-conventional solutions and contrarian positions in deep technology. We champion companies working at the intersection of breakthrough science and transformational technology, led by visionary founders who are equal parts mad scientist and business mastermind.

Emerson Collective invests in entrepreneurs and innovators driven by purpose, seeking consequential companies that deliver both generational impact and venture-scale returns. The firm targets sectors where biggest market opportunities meet meaningful impact levers: energy & environment, digital health, fintech, education, work, and media.

Canaan invests in visionaries with transformative ideas across a 60/40 technology-to-healthcare split. The firm seeks early-stage companies with authentic founder passion, clear problem-solving value, and the potential to improve lives. Canaan runs a transparent, debate-driven partnership with deep operational expertise in healthcare regulation, biotech fundraising, and enterprise scaling.

Invest in bold, visionary founders building transformational businesses long before the world believes in them. We back founders solving impossible-seeming problems across frontier sectors: AI/robotics, crypto, biotech, aerospace, and unconventional ideas.

Partner with exceptional founders to build generational companies that define the world's most critical industries. We provide not just capital but assemble teams of the highest caliber through our 5,000+ member builder community and deep operational expertise.

First-check investors to exceptional founders building category-defining companies and to emerging venture funds reshaping the industry. Formation-stage specialists operating as partners from inception, not simply deploying capital.

We invest in mission-driven companies that dare to tackle impossible challenges, striving to transform industries and create lasting societal impact. We seek founders with audacity to dream big, resilience to persevere, and potential to build forever companies that shape human history.

Backing exceptional, mission-driven entrepreneurs creating companies with Massively Transformative Purpose (MTP) that impact billions of people. We invest across the full innovation lifecycle, from early-stage frontier technology through scale to liquidity. We love companies and individuals that are different, fishing where others aren't, seeking opportunities where exceptional visionary entrepreneurs see novel paths to greatness.

Back the world's most ambitious and transformative entrepreneurs capable of building world-defining companies over 20+ years. Invest in founders with independent thought and first-principles vision to solve humanity's biggest problems across all sectors and geographies.

Invest in companies with compelling stories to tell. We couple capital deployment with media storytelling through the Not Boring newsletter, creating a unique flywheel that amplifies both company and fund narrative.

We invest in relentlessly ambitious entrepreneurs working on fundamental technology and business model innovations that advance humanity toward abundance. Our March to Abundance thesis focuses on four primary areas: (1) freedom from repetitive work through AI and automation, (2) freedom to transact and financial security, (3) freedom from genetic disease and biological limitations, (4) interconnection of humanity through new mediums.

We invest in companies organized around five concrete objectives: improving worldwide health and happiness, promoting resource sustainability, increasing human potential and productivity, increasing knowledge/empathy/connectedness, and disrupting industries that resist these goals. We operate as both investors and company-builders, providing operational expertise and hands-on support far beyond capital.

We invest in technical breakthroughs that overcome the world's greatest challenges. We partner at inception with technically brilliant dreamers who see past impossible to inevitable. We evaluate scientific opportunities through both commercial potential and human impact lenses.

Believe in innovation, risk-taking, and young talent. Best entrepreneurs are rare and precious. Provide quick capital, friendly terms, genuine commitment. Help but don't complicate. Monthly founder support.

AI is a milestone in data maturity progression, not a product category. Argonautic invests in founders building data-centric solutions across infrastructure (horizontal) and vertical markets. Multi-fund structure allows pre-seed to Series B deployment with unified thesis: recognizing verticals at different data adoption stages and deploying capital to those crossing inflection points into AI operationalization.

We invest in proven, transformative technologies that have the potential to be industry-defining while driving meaningful impact on the climate and environment. We partner with founders as active co-developers, not passive investors.

Data is the defensible moat in technology. We invest in companies that build proprietary data assets, analytics capabilities, or machine learning advantages to dominate their categories. Founded on 'information arbitrage' thesis - applying hedge fund quantitative discipline to early-stage venture.

Leverage creator economy and influencer networks to add tangible value to early-stage companies. Invest in ambitious Gen Z founders building consumer products with high influencer marketing potential. Influencer partners actively support portfolio companies with marketing, business development, and strategic partnerships.

Equity of access and representation in venture capital delivers positive returns. Diverse and underrepresented (including LGBTQ+) leaders of high-growth companies deserve capital access. When these founders succeed, they influence ecosystems and open doors for historically excluded groups.

Investing in the picks and shovels of volatility caused by convergent forces (AI, Web3, Deep Science) intersecting with demographic shifts and climate change. We seek to create venture-scale returns by backing bold founders building more equitable, beneficial, transparent, and accessible structures.

Elevate Ventures partners with innovation-driven founders to provide strategic capital, mentorship, and ecosystem access. Founded by a former founder (Governor Mitch Daniels), the firm believes the best founders exhibit grit, creativity, and coachability. They invest across all sectors and geographies but maintain primary focus on Indiana and Great Lakes Region entrepreneurs building cross-sector innovations.

Invest in the most promising Southern European (primarily Italian) deep-technology companies across Advanced Manufacturing, Life Science, and Energy & Environment, and actively support their expansion into Asian markets (China, South Korea, Japan, South-East Asia). The fund uses a proprietary evaluation framework and a 'pull model' — companies must demonstrate genuine Asian market interest before investment.

Startups positioned as transformation partners with Fortune 500 corporates create the most impactful solutions. We believe the next generation of market leaders will emerge through collaborative innovation between startups and incumbent enterprises, supported by global expertise and capital.

Democratize access to venture capital by building large syndicates of non-traditional LPs. Invest across all stages, sectors, and geographies based on founder quality and market conviction, not category restrictions. Enable 2,000+ diverse co-investors to participate alongside marquee firms like Sequoia and Andreessen Horowitz while maintaining founder-friendly economics.

Invest in early-stage tech companies addressing world's largest market opportunities and solving humanity's biggest challenges. Leverage global distributed team to source, evaluate, and support transformational founders.